SOLENO INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][2] Investigation Details - The law firm is reaching out to Soleno stockholders who have suffered losses, encouraging them to discuss their legal rights and options [1][2] - There is no cost or obligation for stockholders to inquire about their rights or the ongoing investigation [2] Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, representing individual and institutional investors in various complex litigations [3] Recent Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's product, Vykat XR, as overpriced and potentially unsafe for children, leading to a significant drop in Soleno's stock price by $5.73 per share, or 7.41%, closing at $71.63 [5]